{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:07:08Z","timestamp":1790831228713,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.phrs.2005.02.013","type":"journal-article","created":{"date-parts":[[2005,3,15]],"date-time":"2005-03-15T07:21:42Z","timestamp":1110871302000},"page":"109-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":123,"title":["Clinical perspectives of PARP inhibitors"],"prefix":"10.1016","volume":"52","author":[{"given":"Grazia","family":"Graziani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2005.02.013_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1124\/pr.54.3.375","article-title":"The therapeutic potential of poly(ADP-ribose) polymerase inhibitors","volume":"54","author":"Virag","year":"2002","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.phrs.2005.02.013_bib2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1023\/A:1022316914492","article-title":"Role of PARP under stress conditions: cell death or protection?","volume":"28","author":"Nicoletti","year":"2003","journal-title":"Neurochem Res"},{"key":"10.1016\/j.phrs.2005.02.013_bib3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/ijc.20342","article-title":"Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions","volume":"111","author":"Beneke","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.phrs.2005.02.013_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0027-5107(01)00111-7","article-title":"Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death","volume":"477","author":"Herceg","year":"2001","journal-title":"Mutat Res"},{"key":"10.1016\/j.phrs.2005.02.013_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pbiomolbio.2004.01.001","article-title":"Poly(ADP-Ribose) Polymerases: Homology, Structural Domains and Functions. Novel Therapeutical Applications","volume":"88","author":"Nguewa","year":"2005","journal-title":"Prog Biophys Mol Biol"},{"key":"10.1016\/j.phrs.2005.02.013_bib6","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1128\/MCB.19.7.5124","article-title":"Failure of poly(ADP-ribose) polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis","volume":"19","author":"Herceg","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.phrs.2005.02.013_bib7","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1006\/bbrc.1997.6491","article-title":"Apoptosis in the absence of poly-(ADP-ribose) polymerase","volume":"233","author":"Leist","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.phrs.2005.02.013_bib8","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1101\/gad.11.18.2347","article-title":"PARP is important for genomic stability but dispensable in apoptosis","volume":"11","author":"Wang","year":"1997","journal-title":"Genes Dev"},{"key":"10.1016\/j.phrs.2005.02.013_bib9","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.4049\/jimmunol.161.7.3753","article-title":"Poly(ADP-ribose) synthetase activation mediates mitochondrial injury during oxidant-induced cell death","volume":"161","author":"Virag","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.phrs.2005.02.013_bib10","doi-asserted-by":"crossref","first-page":"11176","DOI":"10.1074\/jbc.270.19.11176","article-title":"Inactivation of the poly(ADP-ribose) polymerase gene affects oxygen radical and nitric oxide toxicity in islet cells","volume":"270","author":"Heller","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2005.02.013_bib11","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1073\/pnas.95.7.3867","article-title":"Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase","volume":"95","author":"Szabo","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2005.02.013_bib12","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/nm1097-1089","article-title":"Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia","volume":"3","author":"Eliasson","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.phrs.2005.02.013_bib13","doi-asserted-by":"crossref","first-page":"13978","DOI":"10.1073\/pnas.96.24.13978","article-title":"Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion","volume":"96","author":"Ha","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2005.02.013_bib14","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/hh2001.097797","article-title":"Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase","volume":"89","author":"Soriano","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.phrs.2005.02.013_bib15","doi-asserted-by":"crossref","first-page":"G641","DOI":"10.1152\/ajpgi.2000.279.3.G641","article-title":"Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis","volume":"279","author":"Jijon","year":"2000","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.phrs.2005.02.013_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.phrs.2005.02.010","article-title":"Chemopotentiation by PARP inhibitors in cancer therapy","volume":"52","author":"Tentori","year":"2005","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2005.02.013_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/phrs.2001.0935","article-title":"Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors","volume":"45","author":"Tentori","year":"2002","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2005.02.013_bib18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/1567203043480287","article-title":"Temozolomide: an update on pharmacological strategie sto increase its antitumor activity","volume":"1","author":"Tentori","year":"2004","journal-title":"Med Chem Rev-Online"},{"key":"10.1016\/j.phrs.2005.02.013_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0305-7372(97)90019-0","article-title":"Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials","volume":"23","author":"Newlands","year":"1997","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.phrs.2005.02.013_bib20","doi-asserted-by":"crossref","first-page":"23028","DOI":"10.1074\/jbc.M202390200","article-title":"Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1","volume":"277","author":"Schreiber","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2005.02.013_bib21","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1182\/blood.V99.6.2241","article-title":"Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematological malignancy at the CNS site","volume":"99","author":"Tentori","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2005.02.013_bib22","first-page":"5370","article-title":"Systemic administration of GPI 15427 a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma","volume":"9","author":"Tentori","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2005.02.013_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/jnci\/djh005","article-title":"Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG 14361","volume":"96","author":"Calabrese","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.phrs.2005.02.013_bib24","unstructured":"Curtin N., PARP-1: A new target for cancer treatment, Cancer Research UK Scientific YearBook, 2003. 2002\u20132003:52\u201354."},{"key":"10.1016\/j.phrs.2005.02.013_bib25","first-page":"371","article-title":"Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor","volume":"2","author":"Miknyoczki","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.phrs.2005.02.013_bib26","first-page":"415","article-title":"Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors","volume":"26","author":"Tentori","year":"2005","journal-title":"Int J Oncol"},{"key":"10.1016\/j.phrs.2005.02.013_bib27","doi-asserted-by":"crossref","first-page":"39686","DOI":"10.1074\/jbc.M402729200","article-title":"Poly(ADP-ribosyl)ation as a DNA damage-induced post-translational modification regulating poly(ADP-ribose) polymerase-1 topoisomerase I interaction","volume":"279","author":"Yung","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2005.02.013_bib28","doi-asserted-by":"crossref","first-page":"5244","DOI":"10.1074\/jbc.C300437200","article-title":"Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand break resealing","volume":"279","author":"Malanga","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2005.02.013_bib29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/carcin\/20.2.199","article-title":"Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage","volume":"20","author":"Boulton","year":"1999","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.phrs.2005.02.013_bib30","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1038\/sj.onc.1207984","article-title":"Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair","volume":"23","author":"Veuger","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2005.02.013_bib31","doi-asserted-by":"crossref","first-page":"20521","DOI":"10.1074\/jbc.274.29.20521","article-title":"Poly(ADP-ribose) polymerase and Ku autoantigen form a complex and synergistically bind to matrix attachment sequences","volume":"274","author":"Galande","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2005.02.013_bib32","doi-asserted-by":"crossref","first-page":"55117","DOI":"10.1074\/jbc.M404524200","article-title":"Involvement of Poly(ADP-ribose) Polymerase-1 and XRCC1\/DNA Ligase III in an Alternative Route for DNA Double-strand Breaks Rejoining","volume":"279","author":"Audebert","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2005.02.013_bib33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.canlet.2003.10.029","article-title":"Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase","volume":"205","author":"Brock","year":"2004","journal-title":"Cancer Lett"},{"key":"10.1016\/j.phrs.2005.02.013_bib34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.cdd.4400832","article-title":"Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells","volume":"8","author":"Tentori","year":"2001","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.phrs.2005.02.013_bib35","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.1073\/pnas.94.14.7303","article-title":"Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells","volume":"94","author":"de Murcia","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2005.02.013_bib36","first-page":"27","article-title":"Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis","volume":"1552","author":"Tong","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.phrs.2005.02.013_bib37","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/sj.onc.1208289","article-title":"Parp-1 deficiency causes an increase of deletion mutations and insertions\/rearrangements in vivo after treatment with an alkylating agent","volume":"24","author":"Shibata","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2005.02.013_bib38","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/gcc.10250","article-title":"Poly(ADP-ribose) and carcinogenesis","volume":"38","author":"Masutani","year":"2003","journal-title":"Genes Chromosom. Cancer"},{"key":"10.1016\/j.phrs.2005.02.013_bib39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00280-001-0409-z","article-title":"Apoptotic and cytotoxic effects of a methyl sulfonate ester that selectively generates N-3-methyladenine and poly (ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes","volume":"49","author":"Tentori","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.phrs.2005.02.013_bib40","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/nar\/29.3.841","article-title":"Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy","volume":"29","author":"Simbulan-Rosenthal","year":"2001","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.phrs.2005.02.013_bib41","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/nar\/26.8.1891","article-title":"Functional association of poly(ADP-ribose) polymerase with DNA polymerase alpha-primase complex: a link between DNA strand break detection and DNA replication","volume":"26","author":"Dantzer","year":"1998","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.phrs.2005.02.013_bib42","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/MCB.18.6.3563","article-title":"XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage","volume":"18","author":"Masson","year":"1998","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.phrs.2005.02.013_bib43","doi-asserted-by":"crossref","first-page":"11274","DOI":"10.1073\/pnas.200285797","article-title":"Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase","volume":"97","author":"Simbulan-Rosenthal","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2005.02.013_bib44","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.dnarep.2004.06.002","article-title":"PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development","volume":"3","author":"Huber","year":"2004","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.phrs.2005.02.013_bib45","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0002-9440(10)63825-4","article-title":"Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(\u2212\/\u2212) mice","volume":"162","author":"Tong","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.phrs.2005.02.013_bib46","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1349-7006.2003.tb01472.x","article-title":"Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane","volume":"94","author":"Nozaki","year":"2003","journal-title":"Cancer Sci"},{"key":"10.1016\/j.phrs.2005.02.013_bib47","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1093\/emboj\/20.13.3535","article-title":"Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice","volume":"20","author":"Conde","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.phrs.2005.02.013_bib48","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1038\/sj.onc.1203178","article-title":"Overexpression of dominant negative PARP interferes with tumor formation of HeLa cells in nude mice: evidence for increased tumor cell apoptosis in vivo","volume":"18","author":"Hans","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2005.02.013_bib49","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1038\/sj.onc.1207696","article-title":"Crosstalk between PARP-1 and NF-kappaB modulates the promotion of skin neoplasia","volume":"23","author":"Martin-Oliva","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2005.02.013_bib50","doi-asserted-by":"crossref","first-page":"H486","DOI":"10.1152\/ajpheart.00437.2004","article-title":"Increased Expression of Poly (ADP) Ribose Polymerase-1 Contributes to Caspase-Independent Myocyte Cell Death during Heart Failure","volume":"288","author":"Pillai","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.phrs.2005.02.013_bib51","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2119\/2004-00001.Szabo","article-title":"Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation","volume":"10","author":"Szabo","year":"2004","journal-title":"Mol Med"},{"key":"10.1016\/j.phrs.2005.02.013_bib52","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/01.shk.0000136704.26372.2d","article-title":"WY 14643 a potent exogenous PPAR-alpha ligand, reduces intestinal injury associated with splanchnic artery occlusion shock","volume":"22","author":"Cuzzocrea","year":"2004","journal-title":"Shock"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661805000460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661805000460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:50:32Z","timestamp":1760910632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661805000460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S1043661805000460"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2005.02.013","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical perspectives of PARP inhibitors","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2005.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}